Расширенный поиск


Полный текст:


Лечение табачной зависимости у больных хронической обструктивной болезнью легких.

Об авторе

статья Редакционная


Список литературы

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2011 [accessed 01.01.12]. Available from:

2. Sørheim I., Johannesse A., Gulsvik A. et al. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax 2010; 65: 480–485.

3. Jiménez-Ruiz C.A., Masa J., Miravitlles M. et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365–1370.

4. Shahab L., Jarvis M.J., Britton J., West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61: 1043–1047.

5. Grupo de trabajo de GesEPOC. Guia de práctica clinica para el diagnóstico y tratamiento del pacientes con EPOC, Guia española de la EPOC. Arch. Bronconeumol. 2012; 48 (Suppl. 1): 2–58.

6. Pozo F., Alvarez C.J., Castro A. et al. Auditoria clinica de los pacientes hospitalizados por exacerbación de EPOC en España (estudio AUDIPOC): método y organización del trabajo. Arch. Bronconeumol. 2010; 46: 349–357.

7. Clark K.D., Wardrobe-Wong N., Eliot J.J. et al. Cigarette smoke inhalation and lung damage in smokers volunteers. Eur. Respir. J. 1998; 12: 395–399.

8. Hilberink S.R., Jacobs J.E., Schlösser M. et al. Characteristics of patients with COPD in three motivational stages related to smoking cessation. Patient Educ. Couns. 2006; 61: 449–457.

9. Ng T.P., Niti M., Tan W.C. et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch. Intern. Med. 2007; 167: 60–67.

10. Wagena E.J., Kant I.J., Huibers M.J.H. et al. Psychological distress and depressed mood in employees with asthma, chronic bronchitis or emphysema: a population-based observational study on prevalence and the relationship with smoking cigarettes. Eur. J. Epidemiol. 2004; 19: 147–153.

11. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. J.A.M.A. 1994; 272: 1497–1505.

12. Dautzenberg B., Nides M., Kienzler J.L., Callens A. Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges. BMC Clin. Pharmacol. 2007; 8: 11.

13. Tønnesen P., Mikkelsen K.L. Routine smoking cessation with 4 nicotine regiments in a lung clinic. Eur. Respir. J. 2000; 16: 714–722.

14. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334–432.

15. Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in COPD: a network meta-analysis of randomized trials. Eur. Respir. J. 2009; 34: 634–640.

16. Tashkin D.P., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–1575.

17. Wagena E.J., Knispchild P.G., Huibers M.J. et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with COPD. Arch. Intern. Med. 2005; 165: 2286–2292.

18. Tashkin D.P., Rennard S., Hays J.T. et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591–599.

19. Jiménez-Ruiz C.A., Ramos Pinedo A., Cicero Guerrero A. et al. Characterisitics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob. Res. 2012; 14: 1035–1039.

20. Sundblad B.M., Larsson K., Nathell L. High rates of smoking abstinence in COPD patients: smoking cessation by hospitalization. Nicotine Tob. Res. 2008; 10: 883–890.

21. Hoogendoorn M., Feenstra T.L., Hoogenveen R.T., Ruttenvan Mölken M.P.M.H. Long term effectiveness and costeffectiveness of smoking cessation interventions in patients with COPD. Thorax 2010; 65: 711–718.

22. Jimenez Ruiz C.A., Fagerstrom K.O. Diagn„…stico y tratamiento del tabaquismo. Consideraciones generales. In: Jimenez Ruiz C.A., Fagerstrom K.O., eds. Tratado de tabaquismo. 3rd ed. Madrid: Aula Medica; 2011. 289.294.

23. Heatherton T.F., Kozlowsky L.T., Frecker R.C. et al. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 1991; 86: 1119.1127.

24. John U., Meyer C., Schumann A. et al. A short form of the Fagerstrom Test for Nicotine Dependence and the Heaviness of Smoking Index in two adult population samples. Addict. Behav. 2004; 29: 1207.1212.

25. Pomerleau O.F., Fagerstrom K.O., Marks J. et al. Development and validation of a self-rating scale for positive-and negative-reinforcement smoking: the Michigan Nicotine Reinforcement Questionnaire. Nicotine Tob. Res. 2003; 5: 711.718.

26. Jarvis J., Russell M.A.H. Expired air CO: a simple breath of tobacco smoke intake. Br. Med. J. 1980; 281: 484.485.

27. Prochazka J., DiClemente C. Stages and process of selfchange of smoking: towards an integrative model of change. J. Clin. Psychol. 1983; 3: 390.395.

28. Fiore M.C., Jaen C.R., Baker T.B. et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Service; May 2008. Traducci„…n al espanol: Jimenez Ruiz C.A., Jaen C.R., coordinadores de la traducci„…n. Guia de tratamiento del tabaquismo. Sociedad Espanola de Neumologia y Cirugia Toracica, SEPAR. 2010.

29. Barrueco Ferrero M., Jimenez Ruiz C.A., Palomo A. et al. Veracidad de las respuestas de los fumadores en las consultas de deshabituaci„…n tabaquica sobre su abstinencia. Arch. Bronconeumol. 2005; 41: 135.140.

30. Muhammad-Kah R., Liang Q., Frost-Pineda K. et al. Factors affecting exposure to nicotine and carbon monoxide in adult cigarette smokers. Regul. Toxicol. Pharmacol. 2011; 61:129.136.

31. Perez Trullen A., Lazaro Sierra J., Clemente Jimenez L. et al. Marcadores biol„…gicos y funcionales de susceptibilidad, exposici„…n y lesi„…n por el consumo del tabaco. In: Jimenez Ruiz C.A., Fagerstrom K.O., eds. Tratado de tabaquismo. 3rd ed. Madrid: Aula Medica; 2011. 323.340.

32. Hall K., Gibbie T., Lubman D.I. Motivational interviewing techniques-facilitating behaviour change in the general practice setting. Aust. Fam. Physician. 2012; 41: 660.667.

33. Arrol B., Khin N., Kerse N. Screening for depression in primary care with two verbally asked questions: cross-sectional study. Br. Med. J. 2003; 327: 1144.1146.

34. Medici T.C., Unger S., Ruegger M. Smoking pattern of smokers with and without tobacco-related lung diseases. Am. Rev. Respir. Dis. 1985; 131: 385.388.

35. Jimenez Ruiz C.A. Psychological and behavioural interventions for smoking cessation. In: Nardini S., ed. Smoking cessation. Eur. Respir. Monograph. 2008; 42: 61.74.

36. Fagerstrom K.O. Assessment of the patient. In: Nardini S., ed. Smoking cessation. Eur. Respir. Monograph. 2008; 42:44.50.

37. Schunemann H.J., Jaeschke R., Cook D.J. et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am. J. Respir. Crit. Care Med. 2006; 174: 605.614.

38. Bize R., Burnand B., Mueller Y. et al. Evaluacion del riesgo biomedico como ayuda para el abandono del habito de fumar (Revisi„…n Cochrane traducida). In: Biblioteca Cochrane Plus 2009, ‡‚ 3. Oxford: Update Software Ltd.; 2009. Available from: (Traducida de The Cochrane Library, 2009 Issue 2, Art. ‡‚ CD004705. Chichester, UK: John Wiley & Sons, Ltd.).

39. Muller M., Kogler H., Glaab T., Welte T. Use of a lung function screening device for identifying patients at risk for COPD in general practice. Pneumologie 2012; 66:645.649.

40. Pelegrino N.R., Tanni S.E., Amaral R.A. et al. Effects of active smoking on airway and systemic inflammation profiles in patients with chronic obstructive pulmonary disease. Am. J. Med. Sci. 2012,

41. Jimenez Ruiz C.A., Riesco Miranda J.A., Ramos Pinedo A. et al. Recomendaciones para el tratamiento farmacol„…gico del tabaquismo. Propuesta de financiaci„…n. Arch. Bronconeumol. 2008; 44: 213.219.

42. Tonnesen P., Carrozzi L., Fagerstrom K.O. et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J. 2007; 29:390.417.

43. Shiffman S., Fergusson S.G. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008; 103:557.563.

44. Tonstad S., Tonnesen P., Hajek P. et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. J.A.M.A. 2006; 296: 64.71.

45. Ebbert J., Croghan I.T., Sood A. et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob. Res. 2009; 11: 234.239.

46. Ebbert J., Burke M.V., Hays T., Hurt R. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009; 11:572.576.

47. Hajek P., McRobbie H., Myers K. et al. Use of varenicline for4 weeks before quitting smoking. Arch. Intern. Med. 2011; 171: 770.777.

48. Lindson-Hawley N., Aveyard P., Hughes J.R. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst. Rev. 2012; 11; CD008033.

49. Moore D., Aveyard P., Connock M. et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. Br. Med. J. 2009; 338: b1024;

50. Fiore M.C., Baker T.B. Clinical practice. Treating smokers in the health care setting. N. Engl. J. Med. 2011; 365:1222.1231.

51. Hughes J., Rennard S., Fingar J. et al. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine Tob. Res. 2011; 13: 955.964.

Для цитирования:


For citation:


Просмотров: 741

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)